Mylan Pharmaceuticals spent the past decade raising the price of the EpiPen from $57 to $600
. Why? Because they could. The company didn’t have any real competition. And now one competitor, Teva Pharmaceuticals, a company that has tried and failed to bring a generic EpiPen to market before, says that their product won’t be ready until late 2017 or even 2018.
Source: Gizmodo – EpiPen Competitor Says Their Generic Won’t Be Available Until Late 2017 Or 2018